ResMed Inc. vs Eli Lilly & Co.
RMD vs LLY — side-by-side comparison from reported financials. RMD leads 4, LLY leads 7 of 11 comparable metrics.
ResMed Inc.
RMD · Healthcare
$230.05+1.46%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | RMD | LLY |
|---|---|---|
| Price | $230.05 | $1 177.20 |
| Market cap | $32.4B | $1.05T |
| Revenue (TTM) | $5.65B | $79.7B |
| Revenue growth | +10.2% | +31.7% |
| Net margin | 26.9% | 33.5% |
| Free cash flow | $1.65B | $18.2B |
| Net cash (debt) | $643M | ($35.2B) |
| 1-year price return | -17.2% | +37.6% |
| P/E | 21.2 | 41.6 |
| P/E vs own history (cheap-side %) | 91% | 88% |
| Dividend yield | 1.08% | 0.52% |
| Return on equity | 24% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 11,370 | 50,000 |
Full résumé-style profiles: RMD CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.